FOLH1 and prostate cancer: There are ample studies utilizing PSMA‐based imaging agents for tumour detection in prostate cancer,25, 26, 27, 28, 29, 30, 31, 32 high‐grade gliomas33, 34, 35, 36, 37 and lung BMs,34 as well as in follicular thyroid adenoma,38 metastatic renal cell carcinoma39 and melanoma and small‐cell lung cancer (SCLC) xenografts in vivo.40